Development of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato
Microbial Genomics · 2024
DOI: 10.1099/mgen.0.001252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Genomics, 2024. Verfasst von Jonathan T Lee und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research and Development, Pfizer, Inc., Pearl River, NY, 10965, USA. Hauptthemen laut MEDLINE: Antigens, Surface, Bacterial Outer Membrane Proteins, Lipoproteins, Lyme Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Lyme disease (LD), caused by spirochete bacteria of the genus Borrelia burgdorferi sensu lato , remains the most common vector-borne disease in the northern hemisphere. Borrelia outer surface protein A (OspA) is an integral surface protein expressed during the tick cycle, and a validated vaccine target. There are at least 20 recognized Borrelia genospecies, that vary in OspA serotype. This study presents a new in silico sequence-based method for OspA typing using next-generation sequence data. Using a compiled database of over 400 Borrelia genomes encompassing the 4 most common disease-causing genospecies, we characterized OspA diversity in a manner that can accommodate existing and new OspA types and then defined boundaries for classification and assignment of OspA types based on the sequence similarity. To accommodate potential novel OspA types, we have developed a new nomenclature: OspA in silico type (IST). Beyond the ISTs that corresponded to existing OspA serotypes 1–8, we identified nine additional ISTs that cover new OspA variants in B. bavariensis (IST9–10), B. garinii (IST11–12), and other Borrelia genospecies (IST13–17). The IST typing scheme and associated OspA variants are available as part of the PubMLST Borrelia spp. database. Compared to traditional OspA serotyping methods, this new computational pipeline provides a more comprehensive and broadly applicable approach for characterization of OspA type and Borrelia genospecies to support vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine Research and Development, Pfizer, Inc., Pearl River, NY, 10965, USA.
- Pfizer Digital, Pfizer, Inc., Pearl River, NY, 10965, USA.
- Amsterdam University Medical Centers (UMC), location Academic Medical Center (AMC), Department of Internal Medicine, Division of Infectious Diseases, Center for Experimental and Molecular Medicine, Amsterdam Institute f…
Förderung
- Pfizer
Zitieren
APA
Lee, J. T., Li, Z., Nunez, L. D., Katzel, D., Perrin, B. S., Raghuraman, V., Rajyaguru, U., Llamera, K. E., Andrew, L., Anderson, A. S., Hovius, J. W., Liberator, P. A., Simon, R., & Hao, L. (2024). Development of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato. Microbial Genomics. https://doi.org/10.1099/mgen.0.001252
Vancouver
Lee JT, Li Z, Nunez LD, Katzel D, Perrin BS, Raghuraman V, et al. Development of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato. Microbial Genomics. 2024. doi:10.1099/mgen.0.001252
BibTeX
@article{Lee2024,
author = {Lee, Jonathan T and Li, Zhenghui and Nunez, Lorna D and Katzel, Daniel and Perrin, B Scott and Raghuraman, Varun and Rajyaguru, Urvi and Llamera, Katrina E and Andrew, Lubomira and Anderson, Annaliesa S and Hovius, Joppe W and Liberator, Paul A and Simon, Raphael and Hao, Li},
title = {Development of a sequence-based in silico OspA typing method for Borrelia burgdorferi sensu lato},
journal = {Microbial Genomics},
year = {2024},
doi = {10.1099/mgen.0.001252}
}
EUVIMED